## 2 Types of Chaperonopathies in NCPs
\begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Mol. Chap.** & **Mutation** & **Disease** & **M. I.** & **Ref.** \\ \hline c418C-G transversion in exon 2 resulting in & dHMN2B/CMT2F & ADo or & [33] \\ p.Arg140 Gly substitution & dHMN2B/CMT2F & sporadic & [33] \\ c.421A-C transversion in exon 2 resulting in & dHMN2B & ADo & [41] \\ p.Lys141 Gln substitution & dHMN2B & ADo & [36] \\ c.452C-T transition in exon 2 resulting in & dHMN2B & ADo & [36] \\ p.Thr151 Ile substitution & dHMN2B & CMT2F & ADo & [42] \\ c.490A-G transition in exon resulting in & cMT2F & ADo & [42] \\ exon 3 resulting in p.Thr164 Ala substitution & dHMN2B/CMT2F & ADo & [43; 43] \\ p.Thr180 Ile substitution & dHMN2B/CMT2F & ADo & [44] \\ c.544C-T transition in exon 3 resulting in & dHMN2B & ADo & [36] \\ p.Pro182 Leu substitution & dHMN2B & ADo & [32] \\ c.562C-T transition in exon 3 resulting in & CMT2F & Sporadic & [32] \\ p.Arg188 Trp substitution & & Undefined neurologic & & \\ \hline
**HSPE1** & Heterozygous c.217C-T transition in exon 2 resulting in p.Leu173 Phe substitution & Undefined neurologic & & \\ \hline
**DNAJB2** & Homozygous c.14A-G transition in exon 1 resulting in p.Tyr5 Cys substitution & CMT2F/DSMA5 & AR & [46] \\ Homozygous G-A transition in intron 4 (c.229+1G-A) & dHMN/DSMA5 & AR & recessive & [46] \\ Homozygous G-A transition in the donor & DSMA5 & AR & [47] \\ splice site of exon 5 (c.352+1G-A) & & & \\ \hline
**DNAJC5** & Heterozygous c.344T-G transversion in exon 3 resulting in p.Leu115 Arg substitution & CLN4B & ADo & [48; 49; 50; 51] \\ Heterozygous 3-bp deletion in exon 3 (c.346\_348 del) resulting in p.Leu116 del & CLN4B & ADo & [48; 49; 50; 51] \\ \hline
**HSPD1** & Homozygous c.86A-G transition in exon 2 resulting in p.Asp29 Gly substitution & HLD4 or MitCHAP-60 & AR & [52; 53] \\ Heterozygous c.292C-A transition in exon 3 resulting in p.Val98 Ile substitution & SPG13 & ADo & [54] \\ Heterozygous c.1381C-G transversion in & & & \\ exon 10 resulting in p.Gln461 Glu & SPG13 & ADo & [55] \\ substitution & & & \\ \hline
**CCT5** & Homozygous c.440A-G transition in exon 1 resulting in a His147 Arg substitution & Hereditary sensory & & \\ \hline
**CCT5** & Homozygous c.670C-G transversion in exon 5 resulting in Leu224 Val substitution & Demyelinating & & \\ \hline  & c.110A-G transition in exon 1 resulting in & & \\ \hline  & c.110A-G transition in exon 1 resulting in & & \\ \multicolumn{3}{c}{p.Tyr37 Cys substitution} & BBS & AR & [59; 60] \\ \multicolumn{3}{c}{c.155G-A in exon 1 transition resulting in } & BBS & AR & [61] \\ \multicolumn{3}{c}{p.Gly52 Asp substitution} & BBS & AR & [59] \\ \multicolumn{3}{c}{c.169A-G transition in exon 1 resulting in Thr57 Ala substitution} & BBS & AR & [59; 61] \\ \multicolumn{3}{c}{Homozygous 1-bp deletion (c.281 del) in exon 2 resulting in a frameshift after amino acid Phe94 (p.Phe94 fs), terminating the protein at amino acid 103} & BBS & AR & [59; 61] \\ \hline \hline \end{tabular}
\end{table} 
Table 1: _Cont._All the above-mentioned types of chaperopathies, involving the chaperones listed in Table 1 have been implicated in neurological disorders and some examples of these NCPs are discussed below.